Compare JPMorgan Diversified Return International Eqty ETF (JPIN) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Diversified Return International Eqty ETF vs Regeneron Pharmaceuticals Inc — how do they compare? JPMorgan Diversified Return International Eqty ETF trades at $73.01 (market cap $378.77M), while Regeneron Pharmaceuticals Inc trades at $741.17 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 201× JPMorgan Diversified Return International Eqty ETF's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while JPMorgan Diversified Return International Eqty ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Diversified Return International Eqty ETF for 120 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| JPIN | REGN | |
|---|---|---|
Market Cap | $378.77M | $76.14B |
Volume | 13,861 | 500,239 |
52-Week High | $77.80 | $852.03 |
52-Week Low | $64.96 | $557.73 |
Typical Hold Time | 120 Days | 107 Days |
Sector | — | Health |
Enterprise Value | — | $70.85B |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPIN trades at $73.03 with minimal daily movement (+0.12%). Technical indicators signal strong bearish momentum across moving averages and oscillators, though RSI levels suggest potential oversold conditions. The ETF maintains a strategic focus on international value stocks but lacks current fundamental ratio data. Recent dividend activity shows a $0.51 distribution scheduled for September 2026.
The bearish technical setup dominates the near-term outlook, with resistance clustered at $74. Investment appeal hinges on international equity market recovery and the ETF's value strategy execution. Key risks include global market volatility and currency fluctuations affecting international holdings.
Regeneron Pharmaceuticals (REGN) trades at $746.54, up 0.6% on the day, with a bearish technical signal but strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments. Cash flow improved in 2025, and profitability remains robust with a net income margin of 27.86%.
The outlook is positive, driven by the expanded Sanofi partnership and promising clinical trial updates, though technical indicators suggest near-term resistance. Risks include competitive pressures in key drug markets and reliance on successful drug development. Analysts are bullish with a consensus price target of $849.84, indicating potential upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About JPMorgan Diversified Return International Eqty ETF
The fund will invest at least 80% of its assets in securities included in the underlying index. The underlying index is comprised of equity securities across developed global markets (excluding North America) selected to represent a diversified set of factor characteristics.
Read more on JPIN →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
